Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402876/
https://www.ncbi.nlm.nih.gov/pubmed/28458569
http://dx.doi.org/10.2147/CEOR.S138166
_version_ 1783231314462244864
collection PubMed
description
format Online
Article
Text
id pubmed-5402876
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54028762017-04-28 Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum] Clinicoecon Outcomes Res Corrigendum Dove Medical Press 2017-04-19 /pmc/articles/PMC5402876/ /pubmed/28458569 http://dx.doi.org/10.2147/CEOR.S138166 Text en © 2017 Restelli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Corrigendum
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title_full Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title_fullStr Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title_full_unstemmed Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title_short Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
title_sort budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of hiv-positive patients receiving atazanavir-based triple therapies in italy starting from data of the atlas-m trial [corrigendum]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402876/
https://www.ncbi.nlm.nih.gov/pubmed/28458569
http://dx.doi.org/10.2147/CEOR.S138166

Ejemplares similares